Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 17, 2018
Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohortsMatthew J Everly, Mustimbo Roberts, Robert Townsend, et al.Respiratory Research|January 21, 2017
Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPDAsger Reinstrup Bihlet, Morten Asser Karsdal, Jannie Marie Bülow Sand, et al.Human Immunology|December 11, 2025
Belatacept suppresses B-cell subset alloresponsesChethan Ashokkumar, Robert Townsend, Mustimbo Roberts, et al.Breast Cancer Research and Treatment|August 26, 2022
PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancerMariya Rozenblit, Kim Blenman, Malini Harigopal, et al.Neuro-Oncology|May 5, 2022
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoterMichael Lim, Michael Weller, Ahmed Idbaih, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2022
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.JAMA Oncology|April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical TrialKevin J Harrington, Robert L Ferris, Maura Gillison, et al.Cancers|October 13, 2021
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working GroupMieke R Van Bockstal, Maxine Cooks, Iris Nederlof, et al.Pageof 1